Chemotherapy plus pirarubicin in treatment of malignant lymphoma in the elderly:an analysis of 50 cases
- VernacularTitle:化疗辅加吡柔比星治疗老年恶性淋巴瘤50例病例分析
- Author:
Weihong LIU
;
Linjie LI
;
Nengwen XU
;
Zhiguo LIU
- Publication Type:Journal Article
- Keywords:
malignant lymphoma;
pirarubicin;
bone marrow suppression
- From:
Chinese Journal of Biochemical Pharmaceutics
2014;(2):95-96
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the effects and toxicity of pirarubicin and chemotherapy regimen in treatment of malignant lymphoma in the elderly. Methods 50 cases(over 60 years of age) with non Hodgkin's lymphoma collected in Lishui Central Hospital of Zhejiang province from January 2011 to January 2013 were randomly divided into control group(n=25)and experimental group(n=25). Experimental group were received CTOP chemotherapy, control group were received the standard CHOP chemotherapy, vomiting, stomach, blood pressure, blood glucose control and other appropriate symptomatic treatment were adopted according to the speciifc circumstances of each patient in both two groups. Regular inspection were given to all patients, and bone marrow suppression, treatment of lymphoma, complications and other indicators were observed. Results Complete remission in experimental group after treatment was 13 cases, accounted for 52%within group, partial remission were 9 cases, accounted for 36%. The total effective number was 22, and the rate was 88%. Complete remission in control group after treatment was 8 cases, accounted for 32%within group, partial remission were 5 cases, accounted for 20%. The total effective number was 13 cases, and the rate was 52%. Bone marrow suppression in experimental group was signiifcantly less than control group (P<0.05). Conclusion Elderly patients with malignant lymphoma in chemotherapy plus pirarubicin can improve the therapeutic effect, reduce bone marrow suppression and complications.
